Skip to main content

Lung and thoracic.

98 studies recruiting right now, most recently updated first.

Open the Phase 2 page · a list of only those studies

Triangle is made by Triangle Health, Inc.

Lung and thoracic98 studies

NSCLC Stage IVPhase 1/2NCT05950139

Peptide vaccine

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOpen the brief

Non-Small Cell Lung CancerPhase 1/2NCT06088771

Dupilumab

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

Icahn School of Medicine at Mount SinaiOpen the brief

Untreated Stage IV or Recurrent Non-Small Cell Lung CancerPhase 1/2NCT07355205

N-803 + Nivolumab and Ipilimumab

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Washington University School of MedicineOpen the brief

Locally Advanced Lung Non-Small Cell CarcinomaPhase 1NCT05136846

Papaverine

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

Ohio State University Comprehensive Cancer CenterOpen the brief

Lung Non-Small Cell CarcinomaPhase 1NCT06225427Papers

Gilteritinib

Gilteritinib for the Treatment of ALK NSCLC

University of Michigan Rogel Cancer CenterOpen the brief

Non-Small Cell Lung CancerФаза 2NCT07603856

A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy

University of ChicagoOpen the brief

Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ECOG 2)Phase 1NCT04297605

Pembrolizumab + Single-Agent Chemotherapy

Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

University of RochesterOpen the brief

Relapsed/Refractory Small Cell Lung CancerPhase 1NCT07249879

GC511B CAR-T Cell

This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer

Cancer Institute and Hospital, Chinese Academy of Medical SciencesOpen the brief

ALK-Positive Lung Cancer With Brain MetastasesPhase 1/2NCT05987644

Alectinib ± Upfront Radiosurgery

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

Joshua PalmerOpen the brief

Advanced EGFR-Mutant Non-Small Cell Lung CancerPhase 1NCT04762199

MRX-2843 + Osimertinib

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Emory UniversityOpen the brief

Metastatic Non-Small Cell Lung CancerPhase 1NCT05452005

[18F]-αvβ6-BP

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer

University of California, DavisOpen the brief

Clinical trials: Phase 1 and Phase 2, explained